[Dynamics of immunological indices in patients with chronic viral hepatitis B and the effect of thymalin therapy].

Gol'zand IV, Murav'eva NN, Goriacheva LG

Zhurnal mikrobiologii, epidemiologii i immunobiologii1 Aug 1986

PMID2945347PepBankPUB-02945347

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanNon-randomized trialEfficacy outcome
In children with chronic viral hepatitis B, thymalin therapy produced a response including clinico-biochemical remission in 71.6% of cases.
In plain wordsIn children with chronic hepatitis B, thymalin produced a response that included clinical and biochemical remission in 71.6% of cases.
Peptide
Thymalin
Outcome
IncreaseClinico-biochemical remission
Study
n = 102
Children with chronic viral hepatitis B
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated
Measurements
Treatment response
71.6%
cases
Source sentences
Summary
In 71.6% of cases thymalin therapy produced an effect manifested by clinico-biochemical remission, an increase in the number of T-lymphocytes, thermostable cells and the normalization of the T-suppressor/T-helper ratio.
1 context sentence(design, population, supporting numbers)
Summary · context
The work deals with the results of the study of T-lymphocytes and their subpopulations (active, thermostable, theophylline-sensitive and theophylline-resistant) in 102 children with chronic viral hepatitis B, depending on the effectiveness of thymalin therapy.
Report a problemFND-0294534701
02HumanNon-randomized trialMechanism
In responding children with chronic viral hepatitis B, thymalin therapy increased T-lymphocyte numbers.
In plain wordsIn responding children with chronic hepatitis B, thymalin increased T-cell numbers.
Peptide
Thymalin
Outcome
IncreaseT-lymphocyte number
Study
n: not reported in source
Children with chronic viral hepatitis B
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
In 71.6% of cases thymalin therapy produced an effect manifested by clinico-biochemical remission, an increase in the number of T-lymphocytes, thermostable cells and the normalization of the T-suppressor/T-helper ratio.
1 context sentence(design, population, supporting numbers)
Summary · context
The work deals with the results of the study of T-lymphocytes and their subpopulations (active, thermostable, theophylline-sensitive and theophylline-resistant) in 102 children with chronic viral hepatitis B, depending on the effectiveness of thymalin therapy.
Report a problemFND-0294534702
03HumanNon-randomized trialMechanism
In responding children with chronic viral hepatitis B, thymalin therapy increased thermostable cell numbers.
In plain wordsIn responding children with chronic hepatitis B, thymalin increased thermostable immune cell numbers.
Peptide
Thymalin
Outcome
IncreaseThermostable cell number
Study
n: not reported in source
Children with chronic viral hepatitis B
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
In 71.6% of cases thymalin therapy produced an effect manifested by clinico-biochemical remission, an increase in the number of T-lymphocytes, thermostable cells and the normalization of the T-suppressor/T-helper ratio.
1 context sentence(design, population, supporting numbers)
Summary · context
The work deals with the results of the study of T-lymphocytes and their subpopulations (active, thermostable, theophylline-sensitive and theophylline-resistant) in 102 children with chronic viral hepatitis B, depending on the effectiveness of thymalin therapy.
Report a problemFND-0294534703
04HumanNon-randomized trialMechanism
In responding children with chronic viral hepatitis B, thymalin therapy normalized the T-suppressor/T-helper ratio.
In plain wordsIn responding children with chronic hepatitis B, thymalin normalized the ratio of suppressor to helper T cells.
Peptide
Thymalin
Outcome
Direction not reportedT-suppressor/T-helper ratio
Study
n: not reported in source
Children with chronic viral hepatitis B
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
In 71.6% of cases thymalin therapy produced an effect manifested by clinico-biochemical remission, an increase in the number of T-lymphocytes, thermostable cells and the normalization of the T-suppressor/T-helper ratio.
1 context sentence(design, population, supporting numbers)
Summary · context
The work deals with the results of the study of T-lymphocytes and their subpopulations (active, thermostable, theophylline-sensitive and theophylline-resistant) in 102 children with chronic viral hepatitis B, depending on the effectiveness of thymalin therapy.
Report a problemFND-0294534704
05HumanNon-randomized trialMechanism
In responding children with chronic viral hepatitis B, sensitization to HBsAg decreased from 30.5% to 13.9% after thymalin therapy.
In plain wordsIn responding children with chronic hepatitis B, sensitization to HBsAg decreased from 30.5% to 13.9% after thymalin.
Peptide
Thymalin
Outcome
DecreaseSensitization to HBsAg
Study
n: not reported in source
Children with chronic viral hepatitis B
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated
Measurements
Sensitization to HBsAg
30.5%
before treatment
Sensitization to HBsAg
13.9%
after treatment
Source sentences
Summary
In these patients sensitization to HBsAg essentially decreased (from 30.5% to 13.9%), while sensitization to human liver lipoprotein retained its high level even after treatment with thymalin.
1 context sentence(design, population, supporting numbers)
Summary · context
The work deals with the results of the study of T-lymphocytes and their subpopulations (active, thermostable, theophylline-sensitive and theophylline-resistant) in 102 children with chronic viral hepatitis B, depending on the effectiveness of thymalin therapy.
Report a problemFND-0294534705
06HumanNon-randomized trialMechanism
In responding children with chronic viral hepatitis B, sensitization to human liver lipoprotein remained high after thymalin therapy.
In plain wordsIn responding children with chronic hepatitis B, sensitization to human liver lipoprotein remained high after thymalin.
Peptide
Thymalin
Outcome
No significant changeSensitization to human liver lipoprotein
Study
n: not reported in source
Children with chronic viral hepatitis B
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
In these patients sensitization to HBsAg essentially decreased (from 30.5% to 13.9%), while sensitization to human liver lipoprotein retained its high level even after treatment with thymalin.
1 context sentence(design, population, supporting numbers)
Summary · context
The work deals with the results of the study of T-lymphocytes and their subpopulations (active, thermostable, theophylline-sensitive and theophylline-resistant) in 102 children with chronic viral hepatitis B, depending on the effectiveness of thymalin therapy.
Report a problemFND-0294534706

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.